Biotech RadarJobs updated

COMPANY

Iovance Biotherapeutics

HQ: Philadelphia, PA source · iovance.com ↗ · Mid-Atlantic

FDA-approved therapeutic company Clinical Phase 3

24 open jobs · last seen Oct 23, 2026 · 16 sources

Keywords: oncology cancer advanced solid tumor solid tumor Unresectable Melanoma Metastatic Melanoma Non-Small Cell Lung Cancer Melanoma Squamous Cell Carcinoma of the Head and Neck Sarcoma Soft Tissue Sarcoma Advanced Soft Tissue Sarcoma Undifferentiated Pleomorphic Sarcoma Dedifferentiated Liposarcoma Cervical Carcinoma Triple Negative Breast Cancer Colorectal Cancer Head and Neck Squamous Cell Carcinoma Metastatic Non Small Cell Lung Cancer Ocular Melanoma Stage III Non-small Cell Lung Cancer Stage IV Non-small Cell Lung Cancer Primary Central Nervous System Carcinoma Rhabdomyosarcoma Ewing Sarcoma Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Endometrial Cancer Lifileucel LN-145 LN-145-S1 IOV-5001 IOV-3001 IOV-4001 OOS AMTAGVI LN-145/LN-144 IOV-2001

Profile checked Oct 10, 2026

24Open jobs16Trials (company is sponsor)

Hiring

TitleLocation (from posting)Employer postedFirst seen
Clinical Trial ManagerRemoteOct 20, 2026Oct 21, 2026
Computer Systems Validation Analyst IIRemoteOct 16, 2026Oct 17, 2026
Cell Therapy Account Management - North CentralNebraska, North Dakota, South Dakota, and IowaOct 15, 2026Oct 16, 2026
Associate Director, Cell Therapy Non-Personal PromotionsRemoteOct 15, 2026Oct 16, 2026
Cell Therapy Account Management - Indiana/KentuckyIndiana/Kentucky Oct 14, 2026Oct 15, 2026

See all 24 jobs

Trial and FDA signals

Job counts as of Oct 18, 2026. All trial and FDA signals

Timeline

  1. Board tracked Radar started tracking this company’s job board (24 open jobs at last check). source ↗
  2. Trial start Phase 2: A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue Sarcoma source ↗
  3. Trial start Phase 1/Phase 2: A Study of IOV-5001 in Adults With Advanced Solid Tumors source ↗
  4. Trial start Phase 2: A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma source ↗
  5. Trial start Phase 1/Phase 2: A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel source ↗
  6. Trial start Phase 2: A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer. source ↗
  7. Trial start Phase 1: Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants source ↗
  8. Trial start Phase 3: Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma. source ↗
  9. Trial start Phase 1/Phase 2: A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer source ↗
  10. Trial start Phase 2: Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer source ↗
  11. Trial start Phase 1: Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL source ↗
  12. Trial start Phase 2: Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors source ↗
  13. Trial start Phase 2: Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung Cancer source ↗
  14. Trial start Phase 2: Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma source ↗
  15. Trial start Phase 2: Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck source ↗
  16. Trial start Phase 2: Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Open jobs 24

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Clinical Trial ManagerRemoteOct 20, 2026Oct 21, 2026Not stated
Computer Systems Validation Analyst IIRemoteOct 16, 2026Oct 17, 2026Not stated
Cell Therapy Account Management - North CentralNebraska, North Dakota, South Dakota, and IowaOct 15, 2026Oct 16, 2026Not stated
Associate Director, Cell Therapy Non-Personal PromotionsRemoteOct 15, 2026Oct 16, 2026Not stated
Cell Therapy Account Management - Indiana/KentuckyIndiana/Kentucky Oct 14, 2026Oct 15, 2026Senior
Manager, Manufacturing OperationsPhiladelphia, PennsylvaniaOct 8, 2026Oct 9, 2026Mid
Cell Therapy Account Management - Denver, ColoradoDenver, ColoradoOct 7, 2026Oct 9, 2026Senior
Associate Director, Medical Affairs (Medical Science Liaison) – Southeast RegionRemoteOct 7, 2026Oct 9, 2026Senior
Compensation AnalystRemoteOct 6, 2026Oct 9, 2026Mid
Associate Director, Regulatory AffairsRemoteSep 30, 2026Oct 9, 2026Senior
Instrumentation & Equipment Specialist II (3rd Shift Sunday - Wednesday, 10:00pm - 8:30am)Philadelphia, PennsylvaniaSep 24, 2026Oct 9, 2026Mid
Aseptic Manufacturing Technician I - Night Shift A [Contract to Hire]Philadelphia, PennsylvaniaSep 23, 2026Oct 9, 2026Entry
Senior Manager, Clinical Supply PlanningHybridSep 22, 2026Oct 9, 2026Senior
Clinical QA Specialist II, Clinical Specialist Providers (CSP)RemoteSep 15, 2026Oct 9, 2026Mid
Cell Therapy Account Management - North TexasDallas, TexasSep 14, 2026Oct 9, 2026Senior
Production PlannerPhiladelphia, PASep 4, 2026Oct 9, 2026Entry
IT Support Analyst IIPhiladelphia, PASep 1, 2026Oct 9, 2026Mid
Senior Project ManagerPhiladelphia, PAAug 27, 2026Oct 9, 2026Senior
Senior Manager, Cost AccountingiCTCAug 20, 2026Oct 9, 2026Senior
Contract Statistical ProgrammerRemoteJul 24, 2026Oct 17, 2026Not stated
Manager, Investor Relations and Corporate CommunicationsRemoteJul 22, 2026Oct 9, 2026Senior
Manager, Regulatory AffairsRemoteJun 25, 2026Oct 9, 2026Senior
Regulatory Affairs CMC Associate IIRemoteJun 2, 2026Oct 9, 2026Mid
Executive Director, Lifecycle LeaderRemoteApr 1, 2026Oct 9, 2026Executive

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Clinical trials (lead sponsor) 16

RecordTitlePhaseStatusStartPrimary completion
NCT07741877A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue SarcomaPhase 2RecruitingOct 2, 2026Sep 1, 2033 (estimated)
NCT07288203A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced MelanomaPhase 2Active, not recruitingNov 28, 20252027-12 (estimated)
NCT03108495Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical CarcinomaPhase 2TerminatedJun 22, 2017Aug 22, 2025 (actual)
NCT05727904Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.Phase 3RecruitingMar 30, 2023Mar 1, 2028 (estimated)
NCT07743723A Study of IOV-5001 in Adults With Advanced Solid TumorsPhase 1/Phase 2Not yet recruiting2026-092034-03 (estimated)
NCT04614103Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung CancerPhase 2RecruitingMay 7, 20212030-12 (estimated)
NCT06940739A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive LifileucelPhase 1/Phase 2RecruitingMar 11, 20252032-06 (estimated)
NCT05361174A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung CancerPhase 1/Phase 2RecruitingJul 20, 20222027-09 (estimated)
NCT03645928Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid TumorsPhase 2TerminatedMay 7, 2019Feb 20, 2026 (actual)
NCT05398640Expanded Access Program of AMTAGVI That is Out of Specification for Commercial ReleaseNot listedAvailableNot listedNot listed
NCT06566092Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult ParticipantsPhase 1Active, not recruitingMar 28, 20242026-07 (estimated)
NCT02360579Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic MelanomaPhase 2CompletedSep 24, 2015Oct 24, 2024 (actual)
NCT04155710Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLLPhase 1CompletedFeb 19, 2020Nov 11, 2024 (actual)
NCT06481592A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.Phase 2RecruitingOct 29, 20242028-05 (estimated)
NCT03083873Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & NeckPhase 2CompletedJan 9, 2017Aug 8, 2022 (actual)
NCT03419559Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung CancerPhase 2WithdrawnFeb 28, 20182021-12 (estimated)

Connect

See your connections at Iovance Biotherapeutics on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-18

Feedback